Loading...

INM INMED PHARMACEUTICALS INC Expansion Plans 8-K Filing

NMD

NM

INMED PHARMACEUTICALS INC

(INM)

2025 8-K

Financial Results Report

Investment Amendments

Common Shares Offering

Nasdaq Notice Received

Positive Alzheimer Data

Pharmaceutical Outlook

Financial Results Report

Shareholder Meeting

Regulatory Impact Release

Successful Study Completion

Shareholder Meeting Notice

Director Appointment

Financial Results Update

Annual Meeting Notice

Conference Announcement

Investor Meetings

Equity Offerings

Product Expansion

Changes in Registrant’s Cer...

Financial Statements

Other Special Situations

Shareholder Meeting

Director Resignation

Financial Results

Drug Candidate Selection

Patent Announcement

Positive Study Results

Board Elections

Equity Purchase Agreement

Scientific Study Publication

Q1 Financial Results

Share Consolidation

Nasdaq Compliance

Patent Application

Webinar Announcement

Management Change

Financial Results

Annual Meeting Notice

Partnership Announcement

Patent Issuance

Alzheimer's Drug Update

Positive Study Results

Amendment to Offering Agree...

Conference Presentation

Financial Results and Busin...

Management Appointment

Regulation FD Disclosure

Regulation FD Disclosure

Financial Results Announcement

Appointment of CFO and Corp...

Participation in Fireside C...

Regulation FD Disclosure

Annual General Meeting of S...

Financial Results Announcement

Clinical Study Accepted for...

Securities Purchase Agreement

Financial Results

Meeting Announcement

Investor Meetings

Market Expansion

Phase 2 Clinical Trial Results

Presentation of Study Results

Investor Conferences

Announcement of CEO's parti...

Financial Results Announcement

Clinical Trial Completion

Publication of Scientific S...

Announcement of Investor Ev...

Financial Results Announcement

Business Update

External Links:

On November 18, 2025, InMed Pharmaceuticals Inc. reported the successful completion of pharmacokinetic studies for its Alzheimer’s drug candidate INM-901 in large animal models. This is considered a significant advancement for the company.

AI Assistant

INMED PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.